Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Kenneth Brian Gordon MD
Chair, Professor
Department of Dermatology

OFFICE ADDRESS:
The Hub for Collaborative Medicine
8701 Watertown Plank Road
Milwaukee, WI 53226
EDUCATION:
1982 - 1986 BA, Amherst College, Boston, MA
1986 - 1990 MD, Columbia University, College of Physicians and Surgeons, New York, NY
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1990 - 1993 Internship and Residency, Internal Medicine, Beth Israel Hospital/Harvard University, Boston, MA
1993 - 1997 Residency, Dermatology, Northwestern University Medical School, Chicago, IL
FACULTY APPOINTMENTS:
1997 - 2003 Assistant Professor, Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
2003 - 2005 Associate Professor of Medicine, Dermatology, Loyola University of Chicago, Stritch School of Medicine, Chicago, IL
2005 - 2009 Associate Professor, Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
2009 - 2011 Clinical Associate Professor of Medicine, Dermatology, University t of Chicago, Pritzker School of Medicine, Chicago, IL
2011 - 2016 Professor, Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, IL
2016 - Present Professor and Chair, Dermatology, Medical College of Wisconsin, Milwaukee, WI
ADMINISTRATIVE APPOINTMENTS:
1997 - 2003 Director, Psoriasis Treatment Center, Northwestern University, Feinberg School of Medicine, Chicago, IL
1997 - 2003 Medical Director, Dermatology Clinical Trials Unit, Northwestern University, Feinberg School of Medicine, Chicago, IL
1997 - 2002 Chief of Dermatology Service, Lakeside Division, Chicago Veteran's Administrative Medical Center, Chicago, IL
2003 - 2005 Director, Chicago Psoriasis Center at Loyola University, Chicago, IL
2005 - 2011 Head, Dermatology, NorthShore University HealthSystem, Evanston, IL
2005 - 2011 Medical Director, Clinical Trials and Clinical Research Center and the University of Chicago, Pritzker School of Medicine, Evanston, IL
2011 - 2016 Associate Director, Center for Clinical Research of Northwester University Center for Clinical and Translational Science, Northwestern University, Feinberg School of Medicine, Chicago, IL
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:
2003 - 2005 Program Director, Dermatology Residency, Loyola University of Chicago, Stritch School of Medicine, Maywood, IL
SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
American Board of Dermatology
1997
2007
American Board of Dermatology (re-certification)
2005
12/31/2017
American Board of Dermatology (re-certification)
2017
12/31/2027
 
AWARDS AND HONORS:
1986 Akers prize for Most Outstanding Research in Economics, Amherst College
1986 Magna Cum Laude, Amherst College
1995 Young Investor Award , Central Society for Investigating Dermatology
1997 - 1999 Clinical Career Development Award, Dermatology Foundation
1997 Albert Kligman Fellowship, The Society of Investigative Dermatology
2002 - 2003 FOCIS IMID Platform, Federation of Clinical Immunology Societies
2003 - 2008 Editorial Board, Journal of the American Academy of Dermatology
2004 - 2006 Section Editor, Clinical and Basic Research, Dermquest
2004 - 2012 Associate Editor, Journal of Dermatologic Treatment
2004 - 2005 Chair, 13th International Psoriasis Symposium
2005 - Present Named to Best Doctors in America and Who's Who in American Medicine
2006 Chair, First World Conference of Psoriasis and Psoriatic Arthritis
2010 - 2012 Section Editor, Papulosquamous Diseases , Up to Date
2015 Presidential Citation, American Academy of Dermatology
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1998 - 2001 Faculty Senate, Northwestern Medical School
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2001 Committee Chair, National Psoriasis Foundation
2001 - 2002 Board of Directors, National Association of VA Dermatologists
2002 - 2008 Chair, Research Committee, National Psoriasis Foundation
2002 - 2005 Committee on Recertification, American Academy of Dermatology
2002 Founding Member, Psoriasis Specialist Patient Advocacy Group
2002 Delegate and Invited Speaker, Psoriasis Education Summit, American Academy of Dermatology
2007 - 2012 Working Group on Psoriasis and Psoriatic Arthritis, American Academy of Dermatology
2009 - 2014 Co-Chair, Perspectives in Rheumatic Diseases, CME
2009 - 2011 Committee on Retinoids, American Academy of Dermatology
2009 - 2015 Co-Director of CME and Resident Education Meeting, Psoriasis Resident Education Conference
INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2004 - 2006 Chairman of Steering Committee and Scientific Council, 1st World Conference of Psoriasis and Psoriatic Arthritis
2007 - Present Member, International Psoriasis Council
2009 Member of Steering Committee and Scientific Council, 2nd World Conference of Psoriasis and Psoriatic Arthritis
2011 Member of Steering Committee and Scientific Council, 3rd World Conference of Psoriasis and Psoriatic Arthritis
2014 Member of Steering Committee and Scientific Council, 4th World Conference of Psoriasis and Psoriatic Arthritis
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Prior
Non-Peer Review
Title:
A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO-1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X-PLORE)
Source:
Centocor
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2011 - 2013
 
Title:
A 64-Week, Phase 3, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222/MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Source:
Merck
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2011 - 2013
 
Title:
A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long-Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients with Moderate-to-Severe Plaque Psoriasis
Source:
Eli Lilly
Role:
National Prinicipal Investigator
PI:
Kenneth Gordon
Dates:
2012 - 2016
 
Title:
A Phase 1b Randomized, Double-Blinded, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Study the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients with Moderate to Severe Atopic Dermatitis
Source:
Merck
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2012 - 2014
 
Title:
A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE2
Source:
Amgen
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2012 - 2014
 
Title:
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Source:
Janssen National
Role:
National Principal Investigator
PI:
Kenneth Gordon
Dates:
2013 - 2016
 
Title:
A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurativa - PIONEER II
Source:
Abbvie
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2013 - 2014
 
Title:
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long Term Extension Period
Source:
Eli Lilly
Role:
National Principal Investigator
PI:
Kenneth Gordon
Dates:
2013 - 2016
 
Title:
A Phase 3 Open-Label Study of the Sfety and Efficacy of Adalimumab in Subjects with Moderate to Severe Hidradenitis Suppurative - PIONEER (OPEN-LABEL EXTENSION)
Source:
Abbvie
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2014 - 2016
 
Title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-typ Psoriasis with Randomized Withdrawal and Retreatment
Source:
Janssen
Role:
National Principal Investigator
PI:
Kenneth Gordon
Dates:
2014 - 2016
 
Title:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Atopic Dermatitis
Source:
Celgene
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2014 - 2016
 
Title:
A Randomized, Double-Blind, Placebo-Controlled, Study investigating Vaccine Responses in Adults with Moderate to Severe Atopic Dermatitis treated with Dupilumab
Source:
Regeneron
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2015 - 2016
 
Title:
A Randomied, Double-blind, Placebo-controlled, Parallel group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab (300mg) as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis
Source:
Novartis
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2015 - 2016
 
Title:
Open-Label Study to Evaluate the Effect of Elimune Capsules on Biomarkers in Patients with Plaque Psoriasis
Source:
Elorac
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2015
 
Title:
Corrona Psoriasis Registry
Source:
Corrona
Role:
Principal Investigator
PI:
Kenneth Gordon
Dates:
2016
 
Title:
BI 655066 versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)
Source:
Boehringer Ingelheim
Role:
National Principal Investigator
PI:
Kenneth Gordon
Dates:
2016
 
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
Chemoprevention of Non-Melanoma Skin Cancer, Rush Medical College/Cook County Hospital, 2000
The Role of Specific T-Cell Suppression in the Treatment of Atopic Dermatitis, Wayne State University, 2001
Novel Immunomodulating Agents in the Treatment of Inflammatory Skin Disease, University of Wisconsin, 2001
T Cells and the Skin, Rush Medical College/Cook County Hospital, 2001
Anti-TNF Therapy for Psoriasis and Psoriatic Arthritis, University of Miami, Miami, FL, 2002
T Cell Directed Immunotherapy for Psoriasis, Yale University, New Haven, CT, 2003
Psoriasis, Cook County Hospital, Dept. of Internal Medicine, 2003
T Cell Immunomodulation in Dermatology, Emory University, Atlanta, GA, 2003
Strategies for Biologic Therapy in Psoriasis, University of Connecticut, Hartford, CT, 2003
Immunotherapy in Dermatology, Charles M. Howell, Jr. Lectureship, Wake Forest University, Winston-Salem, NC, 2003
Therapy of Psoriasis, University of Illinois, Chicago, IL, 2004
T Cell Directed Immunotherapy for Psoriasis, University of California, Los Angeles, CA, 2004
Anti TNF Therapy of Psoriais: Where Does it Really Fit in?, Mayo Clinic, Rochester, MN, 2004
Immunology of Psoriasis: Clinical Considerations, Lahey Clinic, Burlington, MA, 2005
The Interleukin 12 Family and Psoriasis, University of Pittsburgh, Pittsburgh, PA, 2006
New Pathways in the Treatment of Psoriasis, St. Louis Dermatological Society, St. Louis, MO, 2007
Novel Immunological Pathways in Psoriasis, Indiana University Medical School, Indianapolis, IN, 2007
Psoriasis and Heart Disease, Louisiana State University, New Orleans, LA, 2008
Practical Therapy of Psoriasis and Co-Morbid Disease, University of Tenessee, Memphis, TN, 2008
Practical Therapy of Psoriasis and Co-Morbid Disease, Dartmouth-Hitchcock Medical Center, Lebanon, NH, 2008
Immunology of Psoriasis and Therapeutic Options, Rush University Medical Center, Chicago, IL, 2009
Pathogenesis of Psoriasis and New Treatments, University of Minnesota, Minneapolis, MN, 2009
Traditional and Novel Therapy for Psoriasis, Brown University Medical School, Providence, RI, 2010
The New Understanding of Pathophysiology of Atopic Dermatitis, Case/University Hospital, Cleveland, OH, 2010
The First Psoriasis/Psoriatic Arthritis Co-Managed Clinic, Case/University Hospital, Cleveland, OH, 2010
Therapy for Psoriasis: Where are We Going from Here?, University of Illinois Medical Center, Chicago, IL, 2011
New Approaches for Care of Atopic Dermatitis in Adults, New York University, New York, NY, 2011
New Developments in Understanding Psoriasis, Loma Linda Medical School, Loma Linda, CA, 2014
Goals for Psoriasis Therapy, University of Toronto Department of Dermatology, Toronto, Canada, 2015
Emerging Therapies in Psoriasis, University of Arizona Medical School, Tuscon, AZ, 2015
 
Regional
Midwestern Dermatology Basic Science Conference, Indiana University, 1998 - 2013
Biologic Immunotherapy for Psoriasis, Atlantic Dermatology Society, Baltimore, MD, 2002
Targeted Anti-Cytokine Therapy and Psoriasis, Kansas Dermatological Society, Kansas City, KS, 2002
Biologic Therapies for Psoriasis, Indiana Dermatological Society, Indiana University, 2002
The Use of Immonomodulators in Inflammatory Skin Disease, Missouri Dermatology Society, St. Louis, MO, 2004
Practical Approaches to the Treatment of Psoriasis, Northern New Jersey Dermatological Society, 2006
Novel Immunological Pathways in Psoriasis, Florida Dermatological Society, Palm Beach, FL, 2007
Adalimumab in Psoriasis and Psoriatic Arthritis, Arizona Dermatological Society, Scottsdale, AZ, 2007
New Approaches for Care of Atopic Dermatitis in Adults, Michigan Dermatological Society, Ann Arbor, MI, 2011
The New Science and Treatment of Psoriasis, Connecticut Dermatological Society, Hartford, CT, 2011
 
National
American Academy of Dermatology, 1999 - 2016
New Concepts in Immunotherapy, American Academy of Dermatology Plenary Lecture, 2003
The Use of Biologic Immunotherapy in Dermatology, Philippine Dermatology Society, Manila, Philippines, 2004
Immunology of Psoriasis, Dermatology Foundation Annual Meeting, 2004
Biologic Immunotherapy for Psoriasis, National Dermatology Institute of Singapore, Singapore, 2004
 
International
Establishment of a Model for the Understanding of Targeted Biologic Medications in Psoriasis, International Psoriasis Symposium, 2001
Psoriasis Therapy: What's Next?, European Psoriasis Meeting, Istanbul, Turkey, 2008
The Pathogenesis of Psoriasis, Japanese Center for Psoriasis Research, Hokkaido, Japan, 2008
Long Term Therapy of Psoriasis, Dermatology Society of Rome, Rome, Italy, 2009
Controversies in Psoriasis Therapy, Psoriasis 2010, Paris, France, 2010
Invited lectures on Pathophysiology and Therapy of Psoriasis, European Academy of Dermatology and Venereology, 2010 - 2011
The Impact of Psoriasis on Patients and Therapeutic Approaches, World Congress of Dermatology, Seoul, Korea, 2011
 
BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Gordon KB, Robinson J. Carbon dioxide laser vaporization for Bowen's disease of the finger. Arch Dermatol. 1994 Oct;130(10):1250-2.
2. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer. 1995 Apr 15;75(8):2169-73.
3. Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, Roenigk H, Rosen S. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):304-6.
4. Gordon KB, Garden JM, Robinson JK. Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization. Dermatol Surg. 1996 Aug;22(8):723-8.
5. Katz SK, Gordon KB, Roenigk HH. The cutaneous manifestations of gastrointestinal disease. Prim Care. 1996 Sep;23(3):455-76.
6. Nikcevich KM, Gordon KB, Tan L, Hurst SD, Kroepfl JF, Gardinier M, Barrett TA, Miller SD. IFN-gamma-activated primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells. J Immunol. 1997 Jan 15;158(2):614-21.
7. Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol. 1997 Mar;136(3):415-20.
8. Gordon KB, Roenigk HH, Gendleman M. Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy. Arch Dermatol. 1997 Jun;133(6):691-3.
9. Chan LS, Vanderlugt CJ, Hashimoto T, Nishikawa T, Zone JJ, Black MM, Wojnarowska F, Stevens SR, Chen M, Fairley JA, Woodley DT, Miller SD, Gordon KB. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol. 1998 Feb;110(2):103-9.
10. Tan L, Gordon KB, Mueller JP, Matis LA, Miller SD. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol. 1998 May 01;160(9):4271-9.
11. Ward SK, Roenigk HH, Gordon KB. Dermatologic manifestations of gastrointestinal disorders. Gastroenterol Clin North Am. 1998 Sep;27(3):615-36, vi.
12. Wang C, Quevedo ME, Lannutti BJ, Gordon KB, Guo D, Sun W, Paller AS. In vivo gene therapy with interleukin-12 inhibits primary vascular tumor growth and induces apoptosis in a mouse model. J Invest Dermatol. 1999 May;112(5):775-81.
13. Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A. Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg. 2000 Apr;26(4):371-4.
14. Horn MA, Gordon KB. Chemoprevention of skin cancer. Cancer Treat Res. 2001;106:255-82.
15. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg. 2001 Dec;20(4):242-9.
16. Girvin AM, Gordon KB, Welsh CJ, Clipstone NA, Miller SD. Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood. 2002 May 15;99(10):3692-701.
17. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002 May;138(5):657-63.
18. Gohari S, Gambla C, Healey M, Spaulding G, Gordon KB, Swan J, Cook B, West DP, Lapiere JC. Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg. 2002 Dec;28(12):1107-14; discussion 1114.
19. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 2002;25(13):913-27.
20. Gordon KB, McCormick TS. Evolution of biologic therapies for the treatment of psoriasis. Skinmed. 2003 Sep-Oct;2(5):286-94.
21. Mehlis SL, Gordon KB. The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S44-50.
22. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol. 2003 Nov;49(5):816-25.
23. Adams DR, Gordon KB, Devenyi AG, Ioffreda MD. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol. 2003 Dec;139(12):1540-2.
24. Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A, Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol. 2003 Dec;139(12):1563-70.
25. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A, Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17;290(23):3073-80.
26. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec;139(12):1627-32; discussion 1632.
27. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol. 2003 Dec;2(6):624-8.
28. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17(5):427-31.
29. Mehlis S, Gordon KB. From laboratory to clinic: rationale for biologic therapy. Dermatol Clin. 2004 Oct;22(4):371-7, vii-viii.
30. Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL, EFALIZUMAB STUDY GROUP. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov-Dec;3(6):614-24.
31. Gordon KB, Valentine J. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg. 2004 Dec;8 Suppl 2:3-9.
32. Gordon KB. Patient education and advocacy groups: a means to better outcomes? Arch Dermatol. 2005 Jan;141(1):80-1.
33. Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005 Jan;141(1):82-4.
34. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33.
35. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol. 2005 May;152(5):954-60.
36. Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J, Gamelli R, Nickoloff BJ. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol. 2005 Jun;141(6):683-7.
37. Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005 Sep;27(9):1317-28.
38. Gordon KB, Bonish BK, Patel T, Leonardi CL, Nickoloff BJ. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov;153(5):945-53.
39. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005 Dec;9(6):303-12.
40. Gordon KB, Ruderman EM. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91.
41. Papp KA, Miller B, Gordon KB, Caro I, Kwon P, Compton PG, Leonardi CL, Efalizumab Study Group. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S164-70.
42. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, Caro I, Walicke PA, Wang X, Menter A, Efalizumab Study Group. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May;45(5):605-14.
43. Nickoloff BJ, Bonish BK, Marble DJ, Schriedel KA, DiPietro LA, Gordon KB, Lingen MW. Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc. 2006 Sep;11(1):16-29.
44. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, Heffernan M, Miller B, Hamlin R, Lim L, Zhong J, Hoffman R, Okun MM. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct;55(4):598-606.
45. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, Zitnik R. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat. 2006;17(1):9-17.
46. Melhis SL, Gordon KB. The new psoriasis pathway: toward a unified theory of immunopathogenesis. Expert Rev Clin Immunol. 2007 Jul;3(4):447-50.
47. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007 Jun;143(6):719-26.
48. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, Stevens SR. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr;56(4):598-603.
49. Toor AA, Stiff PJ, Nickoloff BJ, Rodriguez T, Klein JL, Gordon KB. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat. 2007;18(1):13-8.
50. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007;18(6):341-50.
51. Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov;48(2):87-101. PMCID: PMC2703191
52. Langley RG, Gordon KB. Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol. 2007 Dec;6(12):1205-12.
53. Lebwohl M, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008 Jan;58(1):94-105.
54. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J, ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008 Feb;144(2):200-7.
55. Alwawi EA, Mehlis SL, Gordon KB. Treating psoriasis with adalimumab. Ther Clin Risk Manag. 2008 Apr;4(2):345-51. PMCID: PMC2504074
56. Friedewald VE Jr, Cather JC, Gordon KB, Kavanaugh A, Ridker PM, Roberts WC. The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol. 2008 Apr 15;101(8):1119-26.
57. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May;58(5):826-50.
58. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May;58(5):851-64.
59. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665-74.
60. Friedewald VE, Cather JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, Jarratt MT, Krueger JG, Ridker PM, Stone N, Roberts WC. AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol. 2008 Dec 15;102(12):1631-43.
61. Gordon KB, Satoskar R. Therapeutics and immune-mediated skin disease. Curr Dir Autoimmun. 2008;10:359-72.
62. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R, American Academy of Dermatology. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009 Apr;60(4):643-59.
63. Strober B, Berger E, Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb A, Horn EJ, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Menter A, Schwartzman S, Sobell JM, Young M. A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009 Jul;61(1 Suppl 1):S1-S46.
64. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009 Sep;61(3):451-85.
65. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009 Sep-Oct;22(5):431-40.
66. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010 Jan;62(1):114-35.
67. Gordon KB, Gandhi M. Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol. 2010 Feb;146(2):186-8.
68. Gandhi M, Alwawi E, Gordon KB. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010 Mar;29(1):48-52.
69. Krulig E, Gordon KB. Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid. 2010 Jul 27;5:11-22. PMCID: PMC2915500
70. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep;63(3):457-65.
71. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep;63(3):448-56.
72. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, Langley RG, de Lemos JA, Daoud Y, Blankenship D, Kazi S, Kaplan DH, Friedewald VE, Menter A. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24;306(8):864-71.
73. American Academy of Dermatology Work Group, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb A, Koo JY, Lebwohl M, Leonardi CL, Lim HW, Van Voorhees AS, Beutner KR, Ryan C, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011 Jul;65(1):137-74.
74. Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J, ABT-874 Study Investigators. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb;64(2):263-74.
75. Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, Williams DA, Gu Y, Valdes JM. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb;132(2):304-14.
76. Reich K, Papp KA, Griffiths CE, Szapary PO, Yeilding N, Wasfi Y, Ott E, Hsu MC, Lebwohl M, Gordon KB, PHOENIX 1, PHOENIX 2, and ACCEPT investigators. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar;11(3):300-12.
77. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, Guzzo C, Li S, Papp KA. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr;166(4):861-72.
78. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, Guzzo C, Yeilding N, Szapary PO, Fakharzadeh S, Li S, Hsu MC, Reich K. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May;66(5):742-51.
79. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec;2(1):1. PMCID: PMC3510391
80. Strober BE, Clay Cather J, Cohen D, Crowley JJ, Gordon KB, Gottlieb AB, Kavanaugh AF, Korman NJ, Krueger GG, Leonardi CL, Schwartzman S, Sobell JM, Solomon GE, Young M. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb). 2012 Dec;2(1):2. PMCID: PMC3510406
81. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr;72(4):517-24. PMCID: PMC3595151
82. Lingam P, Nwe S, Gordon KB. Systemics to topicals in psoriasis: the unfilled need. Br J Dermatol. 2013 Jul;169(1):2-3.
83. Nwe SM, Champlain AH, Gordon KB. Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013 Jul;9(7):677-82.
84. Blauvelt A, Brown M, Gordon KB, Kavanaugh A, Leonardi CT, Stockfleth E, Strober B, Swanson NA, Martin G. Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol. 2013 Sep;6(9 Suppl):S2-S20. PMCID: PMC3809592
85. Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct;27(10):1252-61.
86. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB, PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45.
87. Zhu B, Edson-Heredia E, Cameron GS, Shen W, Erickson J, Shrom D, Wang P, Banerjee S, Gordon KB. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013 Dec;169(6):1337-41.
88. Gordon KB, Kimball AB, Chau D, Viswanathan HN, Li J, Revicki DA, Kricorian G, Ortmeier BG. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar;170(3):705-15. PMCID: PMC4153951
89. Gordon KB, Strober BE. Understanding therapeutic pathways and comorbidities in psoriasis. Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S20-3.
90. Leonardi CL, Gordon KB. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014 Mar;33(2 Suppl 2):S37-41.
91. Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014 Sep-Oct;24(5):523-32.
92. Gordon KB, Leonardi CL, Lebwohl M, Blauvelt A, Cameron GS, Braun D, Erickson J, Heffernan M. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec;71(6):1176-82.
93. Mercy KM, Gordon KB, Paller AS. Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. JAMA. 2014 Dec 24-31;312(24):2676-7.
94. Gordon KB, Gottlieb AB, Langely RG, van de Kerkhof P, Belasco KT, Sundaram M, Okun M, Serra L. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):767-76.
95. Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, Hu C, Stevens RM, Day RM, Gordon KB, Korman NJ, Griffiths CE. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015 Jul;73(1):37-49.
96. Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09;373(2):136-44.
97. Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct;373(14):1318-28.
98. Edson-Heredia E, Banerjee S, Zhu B, Maeda-Chubachi T, Cameron GS, Shen W, Heffernan MP, Gordon KB, Leonardi CL. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5.
99. Gordon KB. Translating the Science of Psoriasis. Semin Cutan Med Surg. 2016 Jun;35(4 Suppl 4):S64.
100. Armstrong AW, Lynde CW, McBride SR, Ståhle M, Edson-Heredia E, Zhu B, Amato D, Nikaï E, Yang FE, Gordon KB. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01;152(6):661-9.
101. Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, Reich K, Amato D, Ball SG, Braun DK, Cameron GS, Erickson J, Konrad RJ, Muram TM, Nickoloff BJ, Osuntokun OO, Secrest RJ, Zhao F, Mallbris L, Leonardi CL, UNCOVER-1 Study Group, UNCOVER-2 Study Group, UNCOVER-3 Study Group. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28;375(4):345-56.
102. Hsu DY, Gordon K, Silverberg JI. The inpatient burden of psoriasis in the United States. J Am Acad Dermatol. 2016 Jul;75(1):33-41.
103. Strober B, Papp KA, Lebwohl M, Reich K, Paul C, Blauvelt A, Gordon KB, Milmont CE, Viswanathan HN, Li J, Pinto L, Harrison DJ, Kricorian G, Nirula A, Klekotka P. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol. 2016 Jul;75(1):77-82.e7.
104. Hsu DY, Gordon K, Silverberg JI. Serious infections in hospitalized patients with psoriasis in the United States. J Am Acad Dermatol. 2016 Aug;75(2):287-96.
105. Gordon KB, Colombel JF, Hardin DS. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 11 24;375(21):2102.
106. Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, Gordon K. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 02;28(1):3-7.
107. Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. PMCID: PMC5485049
108. Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar;76(3):418-431.
109. Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09;20(8):1174-1179.
110. Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 Jan;178(1):132-139.
111. Gordon KB, Leonardi CL, Furst DE, Bhatia N, Eichenfield LF, Beleznay K. Highlights of Skin Disease Education Foundation's 41st Annual Hawaii Dermatology Seminar™. Semin Cutan Med Surg. 2017 06;36(4S):S52-S59.
112. Kathuria P, Gordon KB, Silverberg JI. Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures. J Am Acad Dermatol. 2017 Jun;76(6):1045-1053.e3.
113. Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017 Dec;77(6):1030-1037.
114. Kimball AB, Augustin M, Gordon KB, Krueger GG, Pariser D, Fakharzadeh S, Goyal K, Calabro S, Lee S, Lin R, Li N, Srivastava B, Guenther L. Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Br J Dermatol. 2018 May 10.
115. Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab versus adalimumab: Results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Apr 28.
116. Zachariae C, Gordon K, Kimball A, Lebwohl M, Blauvelt A, Leonardi C, Braun D, McKean-Matthews M, Burge R, Cameron G. Efficacy and Safety of Ixekizumab Over 4 Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis. J Am Acad Dermatol. 2018 Apr 10.
117. Wu JJ, Armstrong AW, Gordon KB, Menter MA. Practical Strategies for Optimizing Management of Psoriasis. Semin Cutan Med Surg. 2018 Feb;37(2S):S52-S55.
118. Menter MA, Armstrong AW, Gordon KB, Wu JJ. Common and Not-So-Common Comorbidities of Psoriasis. Semin Cutan Med Surg. 2018 Feb;37(2S):S48-S51.
119. Gordon KB, Armstrong AW, Menter MA, Wu JJ. Treating to Target-A Realistic Goal in Psoriasis? Semin Cutan Med Surg. 2018 Feb;37(2S):S44-S47.
120. Armstrong AW, Gordon KB, Menter MA, Wu JJ. The Evolving Landscape of Psoriasis Treatment. Semin Cutan Med Surg. 2018 Feb;37(2S):S39-S43.
121. Gniadecki R, Leonardi CL, Gordon KB, Gu Y, Geng Z, Nader A, Teixeira HD. Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2018 Mar 10.
122. Gottlieb AB, Gordon K, Hsu S, Elewski B, Eichenfield LF, Kircik L, Rastogi S, Pillai R, Israel R. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol. 2018 Mar 06.
123. Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 Feb 28.
 
Books, Chapters, and Reviews
1. Gordon, KB, Chan LS. Infammation and Immunity. In: The Biology of the Skin. D. Woodley and R Freinkel (eds). Parthenon Publishing, 2001.
2. Gordon, KB, West DT. Biologic Therapy in Psoriasis. In: Comprehensive Dermatologic Drug Therapy. S. Wolverton (ed). W.B. Saunders Co., 2001, pp.928-942.
3. Chan LS, Gordon KB. Comparative Immunology: Mouse Immune System. In: Animal Models of Inflammatory Skin Diseases. LS CHAN, (ed). CRC Press, 2004, pp.119-140.
4. Gordon KB, Biologic Immunotherapy of Psoriasis. In: Handbook of Psoriasis, C Camisa, (ed). Blackwell Publishing, 2004, pp.328-337.
5. Gordon, KB, Nickoloff BJ: Adhesion Molecules and INflammatory Cell Migration Pathways in the Skin. In: Skin Immune System, JD Bos (ed). CRC Press, 2004.
6. Gordon, KB, Ruderman, E, eds. Psoriasis and Psoriatic Arthritis: An Integrated Approach. Springer Press. 2005.
7. Ruderman, E, Gordon KB. Clinical Management of Psoriatic Arthriatis and Psoriasis. 2 Editions. Professional Communications Press. 2016.
 
jenkins-FCD Prod-237 8f1a451f877a8b713cb0bc72324b845d75d9edf7